Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Korro Bio, Inc. - Common Stock (NQ: KRRO )

17.88 +0.43 (+2.49%)
Streaming Delayed Price Updated: 2:10 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Korro Bio, Inc. - Common Stock

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
This strategic play will take time to pay off, but it could keep growth going. 
Via The Motley Fool
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ... 
Via Benzinga
Gold Edges Lower; US Homebuilder Sentiment Rises For September
Via Benzinga
Crude Oil Gains Over 1%; US Business Inventories Increase In July
Via Benzinga
Exposures Fossil Fuels
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
Via Benzinga
KRRO Stock Earnings: Korro Bio Misses EPS for Q2 2024
KRRO stock results show that Korro Bio missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023
KRRO stock results show that Korro Bio beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024
KRRO stock results show that Korro Bio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Newly Listed Korro Bio Shares Are Gaining Today
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases. 
Via Benzinga
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?
These stocks are coming off a banner month, but what about the road ahead? 
Via The Motley Fool
Chegg, Perdoceo Education And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.